Organogenesis Holdings Inc. (NASDAQ:ORGO) Position Trimmed by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC decreased its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 74.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,435 shares of the company’s stock after selling 54,494 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in Organogenesis were worth $52,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ORGO. Pallas Capital Advisors LLC acquired a new position in Organogenesis in the 2nd quarter valued at approximately $38,000. Delap Wealth Advisory LLC purchased a new position in shares of Organogenesis during the 2nd quarter valued at $40,000. Allspring Global Investments Holdings LLC increased its stake in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after acquiring an additional 15,369 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Organogenesis by 46.1% during the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after acquiring an additional 7,678 shares in the last quarter. Finally, CWM LLC boosted its position in Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after purchasing an additional 19,242 shares during the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Stock Up 7.7 %

Organogenesis stock opened at $3.08 on Friday. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The firm’s fifty day simple moving average is $2.76 and its 200-day simple moving average is $2.75. The company has a market capitalization of $408.32 million, a P/E ratio of 77.00 and a beta of 1.60.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The company had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million. Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. Sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital began coverage on Organogenesis in a research report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price on the stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.